TD Cowen raises West Pharmaceutical stock target from USD 410 to USD 420

Published on 10/18/2026 at 12:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

West Pharmaceutical stock heads to October 29 results with USD 872.30 million Q2 revenue. Full-year adjusted EPS guidance is USD 8.85-9.05.

Target and earnings dates

TD Cowen lifted its West Pharmaceutical target from USD 410 to USD 420 on October 13, 2026.
Second-quarter 2026 revenue reached USD 872.30 million, up 13.80 percent year over year.
West Pharmaceutical will release third-quarter 2026 results on October 29, 2026.

Reinraum-Fertigung von Vials, West Pharmaceutical, ISIN US9523901012 — West Pharmaceutical (ISIN US9523901012) stellt in sterilen Reinräumen Vials und Elastomer-Verschlüsse für Injektionssysteme her, Illustration mit AI erstellt.

West Pharmaceutical Services stock is heading into a higher-expectation reporting cycle after TD Cowen raised its price target from USD 410 to USD 420 on October 13, 2026, according to Markets Insider. The analyst kept a Buy rating as the company approaches its third-quarter report.

Growth supports the higher target

West reported second-quarter 2026 revenue of USD 872.30 million, up 13.80 percent from the year-earlier quarter, while adjusted earnings per share came in at USD 2.37 versus USD 2.08 expected, according to MarketBeat. The earnings comparison gives the target revision a measurable operating backdrop rather than relying only on valuation sentiment.

For the first half of 2026, revenue totaled USD 1.72 billion and adjusted earnings per share reached USD 4.50, according to Zacks. Management raised full-year organic revenue growth guidance to 10-11 percent and set adjusted earnings per share guidance at USD 8.85-9.05.

Three dated steps shaped the story

On July 23, 2026, West reported second-quarter revenue of USD 872.30 million and adjusted earnings per share of USD 2.37, according to MarketBeat. On October 8, 2026, West announced that third-quarter results would be released before the US market opens on October 29, 2026, according to West Pharmaceutical Services. On October 13, 2026, TD Cowen raised its target from USD 410 to USD 420.

What does the target change mean?

The USD 420 target is 9.37 percent above the USD 384.02 last price on the NYSE at 4:00 p.m. EDT on October 16, 2026. That gap leaves the October 29 report as the next test for the raised outlook, particularly after the company set third-quarter adjusted earnings per share guidance at USD 2.14-2.24.

October 29 results set the next date

West will publish third-quarter 2026 financial results before the US market opens on October 29, 2026, followed by a conference call at 8:00 a.m. EDT, according to West Pharmaceutical Services. The release will show whether the second-quarter growth rate and the 10-11 percent organic revenue outlook are holding into the second half.

NYSE valuation leaves execution in focus

West Pharmaceutical Services had a market capitalization of USD 27.0 billion and a 52-week range of USD 223.83 to USD 386.26 as of October 16, 2026. Its last NYSE price of USD 384.02 stood USD 2.24 below that high, keeping the forthcoming results close to the upper end of the annual range.

The further course of trading is shown by the continuously updated real-time quote of West Pharmaceutical stock.